Takayasu
arteritis (TA) is a debilitating, systemic disease that
involves the aorta and large arteries in a chronic inflammatory process
that leads to vessel stenosis. Initially, the disease remains clinically
silent (or remains undetected) until the patients present with vascular
occlusion. Therefore, new methods for appropriate and timely diagnosis
of TA cases are needed to start proper therapy on time and also to
monitor the patient’s response to the given treatment. In this
context, NMR-based serum metabolomic profiling has been explored in
this proof-of-principle study for the first time to determine characteristic
metabolites that could be potentially helpful for diagnosis and prognosis
of TA. Serum metabolic profiling of TA patients (n = 29) and healthy controls (n = 30) was performed
using 1D 1H NMR spectroscopy, and possible biomarker metabolites
were identified. Using projection to least-squares discriminant analysis,
we could distinguish TA patients from healthy controls. Compared to
healthy controls, TA patients had (a) increased serum levels of choline
metabolites, LDL cholesterol, N-acetyl glycoproteins (NAGs), and glucose
and (b) decreased serum levels of lactate, lipids, HDL cholesterol,
and glucogenic amino acids. The results of this study are preliminary
and need to be confirmed in a prospective study.